Document 3GKoBV5kr3J1EYG4BROyYEVn

FROM; 366-52SE CHARLES F. REINHARDT, M.D. Haskell Laboratory CR&DiDepti Please find attached copy(s) of Follow-Up Hazard Determination letter for your approval. ^ Please sign and return for processing to C.F. Reinhardt, Haskell 1. ''S N 27661 DUP040010881 EStASLlSH&O 1002 E. I. d u Po n t d e Ne mo u r s &.Co mp a n y vINCORP^^Xt EP' Ha s k e l l La b o r a t o r y f o r To x ic o l o g y a n d In d u s t r ia l Me d ic in e P.O. Bex 50, El k t o n Ro a d Ne w a r k , De l a w a r e 19714 .CENTRAL RESEARCH AND: DEVELOPMENT DEPARTMENT ce: B.W. Karrh, ERD, N-13510 R.C. Graham. A.M. Kaplan N.D. Krivanek Central File March 5, 1990 TO: G.J, Patterson Automotive Products Dept* t B-5222 FROM: C.F. Reinhardt, M.D. Cf/9 CR&D Dept. Haskell Laboratory R.N. Ugo, M.D. ER Dept. B-114&0 m'i "^ Lead Naphthenate CAS.Registry No. 61790-14-5 Ref.: Hazard Determination Letter of 4/10/89 G.J. Patterson's Letter of 5/23/89 G.J. Patterson's Memo of 1/17/90 G.J. Patterson's Memo of 1/26/90 Hazard Determination Letter of 7/10/89 (Lead and Lead Compounds) P.G. Gilby's Letter of 10/18/89 This letter is being written to complete the follow-up to the hazard determination and, development of control programs as prescribed in the EQC Guidelines II C-l, "Control of Carcinogenicp Reproductive and Developmental Risks Posed by Chemicals Made or Used within Du Pont1'. Your letter of May 23, 1989 and memos referenced above, indicate that the potential for employee exposure to airborne lead naphthenate is in compliance with the recommended AEL of 50 ug/m3 (8-hour TWA)-skin, and that industrial hygiene practices, work practices and engineering controls are appropriate. Additionally, you indicated that the toxicological data for lead naphthenate have been communicated to all concerned employees, N 27661.01 DUP040Q10882 Further, you stated that APD employees were informed concerning the hazard determination for lead and lead compounds, are now reviewing your blood-lead data, and will be developing control plans aimed at achieving the new blood-lead goal of less than 15 ug/dl for all females of child bearing capability and of less than 35 ug/dl for all other employees. Based on this information, we believe the communications and control programs for lead naphthenate are appropriate. B.V. Karrh, M.D., Vice President of Safety1, Health and Environmental Affairs agrees with this assessment. AMK/alr<2.50) DUP040010883